Pre-made Pavurutamab biosimilar ( Bispecific scFv, anti-TNFRSF17;CD3E therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-433
Anti-TNFRSF17;CD3E therapeutic antibody (Pre-made Pavurutamab biosimilar,Bispecific scFv) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Pavurutamab (formerly AMG 701) is a half-life extended (HLE) anti-B-cell maturation antigen (BCMA) x anti-CD3 BiTE (bispecific T cell engager) molecule. It is being investigated for the treatment of multiple myeloma.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-TNFRSF17;CD3E therapeutic antibody (Pre-made Pavurutamab biosimilar,Bispecific scFv)|
|Highest_Clin_Trial (Jan '20)||Phase-I|
|100% SI Structure||None;None|
|99% SI Structure||None;None|
|95-98% SI Structure||None;None|
|Conditions Active||Multiple myeloma|
|Development Tech||BiTE Technology|